FAQS Frequently asked questions

Following intravenous administration, ICG binds rapidly to plasma proteins and remains predominantly within the vascular system. It is taken up by the liver and excreted unchanged into the bile, without being metabolised.

Depending on the country, approved uses may include cardiac, circulatory and microcirculatory diagnostics; liver-function diagnostics; ophthalmic angiography diagnostics; and breast sentinel lymph-node mapping. The precise indication, route of administration and dosing vary by market. Please consult the local Summary of Product Characteristics.

Verdye is administered intravenously for a number of approved diagnostic applications. Intradermal administration is also approved for breast sentinel lymph-node mapping in certain countries. Healthcare professionals must use the route described in the locally approved product information.

Verdye is supplied as a sterile, lyophilised powder in a vial for reconstitution before use. The vial presentation allows the healthcare professional to withdraw the volume required for the approved application and individual patient, in accordance with the local Summary of Product Characteristics.

This provides flexibility across different indications, patient weights and dosing requirements. Verdye™ is intended for single use, and any unused product must be discarded in accordance with the local product information.

The vial presentation allows the healthcare professional to prepare and withdraw the volume required for the approved application and individual patient. The vial also supports controlled reconstitution and withdrawal using established aseptic techniques. Healthcare professionals should always consult the locally approved product information.

Depending on the country and approved indication, Verdye may be administered:

• intravenously for cardiac, circulatory and microcirculatory diagnostics, liver-function diagnostics and ophthalmic angiography; and
• intradermally for fluorescence-guided sentinel lymph-node mapping in breast cancer.

The approved indications, routes, doses and preparation instructions vary by country. Healthcare professionals must consult the locally approved Summary of Product Characteristics.

Intradermal administration places ICG within the superficial tissue, where it can enter the local lymphatic vessels and travel towards the draining sentinel lymph nodes. A compatible near-infrared imaging system can then be used to visualise the lymphatic pathway and support sentinel lymph-node identification during surgery.

This route is specifically approved for breast sentinel lymph-node mapping in applicable countries. Verdye should be prepared and administered in accordance with the locally approved Summary of Product Characteristics.

Intradermal administration supports rapid lymphatic uptake and real-time visualisation of lymphatic flow using a compatible near-infrared imaging system. It can allow the surgical team to visualise the pathway towards the sentinel lymph nodes and provide additional intraoperative information during node identification.

Because the approved route is clearly defined in the product information, healthcare professionals have established instructions covering preparation, dose and administration for this application.

Yes. The vial presentation provides flexibility across a range of approved diagnostic and fluorescence-imaging applications. The appropriate route, dose, reconstitution volume and administration technique depend on the indication and local authorisation.

This flexibility allows healthcare professionals to prepare Verdye according to the specific clinical application and individual patient, while working within the locally approved prescribing information.

Verdye must be reconstituted using the diluent and volume specified in the locally approved product information. Preparation should be performed by a healthcare professional using an aseptic technique. The solution should be visually inspected and used only if it meets the appearance requirements stated in the product information.

Verdye should be stored in accordance with the conditions specified in the locally approved product information. Healthcare professionals should check the expiry date and storage requirements before use and should not use the product if the packaging or vial is damaged.

The dose depends on the approved indication, route of administration, patient age and body weight. Please consult the locally approved Summary of Product Characteristics for complete dosing and maximum daily-dose information. This website FAQ is not a substitute for prescribing information.

No. Verdye is intended for single patient use only. Any unused product or solution should be discarded in accordance with the local product information and institutional procedures.

Follow the in-use storage and disposal instructions in the locally approved Summary of Product
Characteristics. Do not retain or reuse the reconstituted solution beyond the permitted period.

Following intravenous administration, ICG circulates rapidly. The time to visualisation depends on the injection site, the patient’s circulation, the clinical application and the imaging protocol.

Whether and when a measurement may be repeated depends on the clinical application, the patient and the cumulative dose administered. Healthcare professionals should follow the locally approved product information and observe the applicable maximum daily dose.

Available vial strengths and pack configurations vary by country. Consult the local product information or contact Diagnostic Green or your local distributor for current availability.

As with all medicinal products, Verdye can cause adverse reactions. Serious hypersensitivity reactions, including anaphylactic reactions, have been reported. Appropriate emergency equipment and trained personnel should be available when it is administered. Consult the local Summary of Product Characteristics for complete contraindications, warnings, precautions and adverse-reaction information.

Availability, approved indications and presentations vary by country. Contact Diagnostic Green or your local distributor for market-specific information.

Healthcare professionals and patients should report suspected adverse reactions through the appropriate national reporting system and the contact provided in the local product information.

Suspected adverse reactions associated with Verdye should be reported to:
Email: ICG@drugsafety.de
Telephone: +49 171 3860445

Product-quality complaints and medical-information enquiries should be submitted separately to:
Email: < a href="mailto:info@diagnosticgreen.com">info@diagnosticgreen.com

Fluorescence occurs when a substance absorbs light at one wavelength and emits light at a longer wavelength. In fluorescence imaging, the emitted light is detected by a specialised camera and translated into an image for the clinical team.

Conventional white-light vision remains fundamental to surgery, but some anatomical structures and physiological differences can be difficult to distinguish by sight alone. Fluorescence imaging provides additional visual information during the procedure and may support the assessment of blood flow, lymphatic pathways or selected anatomical structures, depending on the approved application.

CT, MRI, ultrasound and other preoperative imaging modalities provide important information before surgery. Fluorescence imaging is used during the procedure and displays fluorescence in real time. It is an adjunct to, rather than a replacement for, established imaging, surgical judgement and standard methods of assessment.

No. Near-infrared fluorescence imaging does not use ionising radiation. It uses near-infrared excitation light together with a compatible fluorescent agent and imaging system.

Indocyanine green (ICG) is a near-infrared fluorescent agent that has been used in medical diagnostics for decades. Following intravenous administration, it binds rapidly to plasma proteins, circulates through the vascular system and is cleared by the liver into the bile.

A compatible imaging system illuminates the area with near-infrared excitation light. ICG absorbs this light and emits fluorescence at a longer wavelength. The imaging system detects the emitted light and displays it for the clinical team.

Near-infrared fluorescence can be detected beneath the tissue surface, but imaging depth is limited. Visibility depends on tissue type and thickness, the amount and distribution of fluorescent agent, ambient light and the imaging system being used.

The route, dose and timing depend on the medicinal product, approved indication and country.
Administration may be intravenous or, for certain locally approved applications, intradermal. Healthcare professionals must follow the locally approved prescribing information and their institution’s clinical protocol.

Not necessarily. The fluorescence displayed by a conventional imaging system provides visual information about the distribution and relative intensity of the fluorescent agent. The appearance of fluorescence can be influenced by factors including dose, timing, imaging distance, angle, tissue characteristics, ambient light and camera settings. Unless the camera system includes a specifically validated quantification function, fluorescence intensity should not be interpreted as an absolute measurement of perfusion.

Fluorescence imaging systems are available for open, laparoscopic, endoscopic and robotic procedures. The selected system must be compatible with the fluorescent agent and intended application. See our compatible imaging systems page or consult the system manufacturer.

ICG medicinal products are authorised in many countries, but product availability, approved indications, doses and routes of administration vary. Healthcare professionals should consult the locally approved product information.

No. Fluorescence imaging provides adjunctive visual information. Findings must be interpreted together with the patient’s clinical circumstances, conventional visual assessment, other available information and the healthcare professional’s judgement.

Failure to detect fluorescence may relate to system setup, ambient light, imaging distance, timing, administration or other clinical and technical factors. Confirm that the imaging system has been set up and operated in accordance with its Instructions for Use. Preparation and administration of ICG must follow the locally approved product information and the institution’s clinical protocol. Do not administer an additional dose solely on the basis of this FAQ.

Contact Diagnostic Green, your local distributor or the imaging-system manufacturer.

Diagnostic Green also provides education and training resources for healthcare professionals.

Verdye is indicated for ophthalmic angiography diagnostics, including measurement of perfusion of the choroid. Approved wording may vary by country; healthcare professionals should consult the locally approved Summary of Product Characteristics.

ICG emits fluorescence in the near-infrared region and binds strongly to plasma proteins. These properties support visualisation of the deeper choroidal circulation, including through pigment and, in some circumstances, fluid or haemorrhage that may limit visualisation with visible-light techniques.

ICGA provides information about choroidal vascular perfusion and patterns of fluorescence. In clinical practice, ophthalmologists may use this information alongside examination and other imaging modalities when assessing choroidal and retinal disease. Interpretation and use should follow local product information, clinical guidance and the ophthalmologist’s judgement.

Fluorescein angiography primarily visualises the retinal circulation, while the near-infrared properties of ICG and its high degree of protein binding support visualisation of the deeper choroidal circulation. The two modalities provide different and often complementary clinical information.

ICGA uses an intravenously administered fluorescent agent to provide dynamic information about choroidal fluorescence over time. Optical coherence tomography angiography (OCTA) is non-invasive and provides depth-resolved visualisation of blood flow, but images may be affected by motion, segmentation and other artefacts. The techniques are complementary, and the appropriate choice depends on the clinical question being asked by the clinician.

ICGA requires an ophthalmic imaging system capable of near-infrared excitation and detection at wavelengths appropriate for ICG. Users should follow the imaging-system manufacturer’s instructions and the local prescribing information for Verdye.

Verdye must be prepared and administered by a healthcare professional in accordance with the locally approved Summary of Product Characteristics. The dose is determined according to the approved indication and the individual patient. This website FAQ is not a substitute for prescribing information.

ICGA is generally observed over a sequence of early, intermediate and later phases after administration. The timing and duration of image acquisition depend on the clinical question, imaging protocol and equipment being used.

As with all medicinal products, Verdye can cause adverse reactions, including rare serious hypersensitivity reactions. Appropriate emergency equipment and trained personnel should be available. Healthcare professionals should consult the local Summary of Product Characteristics for complete contraindications, warnings, precautions and adverse-reaction information.

Healthcare professionals can access the locally approved Verdye product information and Diagnostic Green’s ophthalmology resources online. For medical-information enquiries, contact Diagnostic Green or your local representative.

Healthcare professionals and patients should report suspected adverse reactions through the appropriate national reporting system and the contact provided in the local product information.

Suspected adverse reactions associated with Verdye should be reported to:

Email: ICG@drugsafety.de
Telephone: +49 171 3860445

Product-quality complaints and medical-information enquiries should be submitted separately to:
Email: info@diagnosticgreen.com